IL106981A - Use of active-direct thrombin monitoring for the production of medical products that have thrombolytic activity - Google Patents
Use of active-direct thrombin monitoring for the production of medical products that have thrombolytic activityInfo
- Publication number
- IL106981A IL106981A IL10698193A IL10698193A IL106981A IL 106981 A IL106981 A IL 106981A IL 10698193 A IL10698193 A IL 10698193A IL 10698193 A IL10698193 A IL 10698193A IL 106981 A IL106981 A IL 106981A
- Authority
- IL
- Israel
- Prior art keywords
- thrombin inhibitor
- direct
- manufacture
- acting thrombin
- thrombolytic activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9210833A FR2695562B1 (fr) | 1992-09-11 | 1992-09-11 | Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un médicament à activité thrombolytique. |
Publications (2)
Publication Number | Publication Date |
---|---|
IL106981A0 IL106981A0 (en) | 1993-12-28 |
IL106981A true IL106981A (en) | 1999-03-12 |
Family
ID=9433400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10698193A IL106981A (en) | 1992-09-11 | 1993-09-10 | Use of active-direct thrombin monitoring for the production of medical products that have thrombolytic activity |
Country Status (18)
Country | Link |
---|---|
US (1) | US5583113A (xx) |
EP (1) | EP0589741B1 (xx) |
JP (1) | JPH06228007A (xx) |
KR (1) | KR100261526B1 (xx) |
CN (1) | CN1066961C (xx) |
AT (1) | ATE163856T1 (xx) |
AU (1) | AU4628193A (xx) |
CA (1) | CA2105888C (xx) |
CZ (1) | CZ188893A3 (xx) |
DE (1) | DE69317343T2 (xx) |
DK (1) | DK0589741T3 (xx) |
ES (1) | ES2115741T4 (xx) |
FR (1) | FR2695562B1 (xx) |
IL (1) | IL106981A (xx) |
NO (1) | NO306537B1 (xx) |
SK (1) | SK96993A3 (xx) |
TW (1) | TW284691B (xx) |
ZA (1) | ZA936707B (xx) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830448A (en) * | 1994-06-16 | 1998-11-03 | Genentech, Inc. | Compositions and methods for the treatment of tumors |
DE4421052A1 (de) | 1994-06-17 | 1995-12-21 | Basf Ag | Neue Thrombininhibitoren, ihre Herstellung und Verwendung |
MX9706069A (es) * | 1995-02-17 | 1997-10-31 | Basf Ag | Nuevos inhibidores de la trombina. |
US5840733A (en) * | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
IL136139A0 (en) | 1998-01-26 | 2001-05-20 | Basf Ag | Thrombin inhibitors |
CN101598725B (zh) * | 2009-06-23 | 2012-07-18 | 南通大学附属医院 | 阿加曲班在血细胞和生化常规分析中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4258192A (en) * | 1977-12-16 | 1981-03-24 | Mitsubishi Chemical Industries Limited | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
US4318904A (en) * | 1980-04-25 | 1982-03-09 | Research Corporation | Peptide affinity labels for thrombin and other trypsin-like proteases |
US4929602A (en) * | 1987-11-25 | 1990-05-29 | Scripps Clinic And Research Foundation | Method of inhibiting platelet dependent arterial thrombosis |
US5196404B1 (en) * | 1989-08-18 | 1996-09-10 | Biogen Inc | Inhibitors of thrombin |
-
1992
- 1992-09-11 FR FR9210833A patent/FR2695562B1/fr not_active Expired - Fee Related
-
1993
- 1993-09-02 ES ES93402136T patent/ES2115741T4/es not_active Expired - Lifetime
- 1993-09-02 DE DE69317343T patent/DE69317343T2/de not_active Expired - Lifetime
- 1993-09-02 DK DK93402136T patent/DK0589741T3/da active
- 1993-09-02 EP EP93402136A patent/EP0589741B1/fr not_active Expired - Lifetime
- 1993-09-02 AT AT93402136T patent/ATE163856T1/de not_active IP Right Cessation
- 1993-09-10 CA CA002105888A patent/CA2105888C/fr not_active Expired - Lifetime
- 1993-09-10 KR KR1019930018230A patent/KR100261526B1/ko not_active IP Right Cessation
- 1993-09-10 IL IL10698193A patent/IL106981A/en not_active IP Right Cessation
- 1993-09-10 TW TW082107438A patent/TW284691B/zh active
- 1993-09-10 JP JP5225606A patent/JPH06228007A/ja active Pending
- 1993-09-10 NO NO933235A patent/NO306537B1/no not_active IP Right Cessation
- 1993-09-10 CZ CZ931888A patent/CZ188893A3/cs unknown
- 1993-09-10 ZA ZA936707A patent/ZA936707B/xx unknown
- 1993-09-10 CN CN93117197A patent/CN1066961C/zh not_active Expired - Lifetime
- 1993-09-10 SK SK969-93A patent/SK96993A3/sk unknown
- 1993-09-10 AU AU46281/93A patent/AU4628193A/en not_active Abandoned
-
1995
- 1995-02-13 US US08/387,382 patent/US5583113A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2105888A1 (fr) | 1994-03-12 |
NO933235D0 (no) | 1993-09-10 |
CA2105888C (fr) | 2008-04-15 |
FR2695562A1 (fr) | 1994-03-18 |
CN1066961C (zh) | 2001-06-13 |
IL106981A0 (en) | 1993-12-28 |
NO306537B1 (no) | 1999-11-22 |
JPH06228007A (ja) | 1994-08-16 |
AU4628193A (en) | 1994-03-17 |
ES2115741T4 (es) | 2012-07-04 |
ATE163856T1 (de) | 1998-03-15 |
US5583113A (en) | 1996-12-10 |
NO933235L (no) | 1994-03-14 |
ES2115741T3 (es) | 1998-07-01 |
CN1087015A (zh) | 1994-05-25 |
KR100261526B1 (ko) | 2000-07-15 |
EP0589741A1 (fr) | 1994-03-30 |
TW284691B (xx) | 1996-09-01 |
DK0589741T3 (da) | 1998-12-21 |
ZA936707B (en) | 1994-03-30 |
FR2695562B1 (fr) | 1994-10-14 |
SK96993A3 (en) | 1994-08-10 |
DE69317343T2 (de) | 1998-10-08 |
KR940006600A (ko) | 1994-04-25 |
DE69317343D1 (de) | 1998-04-16 |
CZ188893A3 (en) | 1994-03-16 |
EP0589741B1 (fr) | 1998-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lidon et al. | Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. | |
DE69503120T2 (de) | Zusammensetzungen aus einer thrombolytisch wirkende substanz und antikoagulantien, und ihre verwendungen | |
US6235279B1 (en) | Method for treating thromboembolic conditions by inhibiting reocclusion via the use of multiple bolus administration of thrombolytically active proteins | |
IL106981A (en) | Use of active-direct thrombin monitoring for the production of medical products that have thrombolytic activity | |
Weiss et al. | Effect of aspirin and dipyridamole on the interaction of human platelets with sub-endothelium: studies using citrated and native blood | |
US5055295A (en) | Lysis of fibrin blood clots with urokinase and pro-urokinase | |
Sobel et al. | Coronary thrombolysis with facilitated absorption of intramuscularly injected tissue-type plasminogen activator. | |
Bode et al. | Absence of drug interaction between heparin and nitroglycerin: randomized placebo-controlled crossover study | |
Spivey et al. | Plasma catecholamine levels after intraosseous epinephrine administration in a cardiac arrest model | |
Kurz et al. | Effects of intracoronary low-dose enalaprilat as an adjunct to primary percutaneous transluminal coronary angiography in acute myocardial infarction | |
Kerins et al. | Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. | |
Werns et al. | Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis | |
Hanson et al. | Effect of dazoxiben on arterial graft thrombosis in the baboon. | |
EP0265129A1 (en) | Thrombolytic therapy | |
Dembińska-Kieć et al. | Effect of prostacyclin (PGI2) on platelets and fibrinolytic activity in patients with arteriosclerosis obliterans | |
EP0223192B1 (en) | Pharmaceutical composition having thrombolytic activity | |
US3790672A (en) | Method for activating blood fibrinolysis by administration of a salt of 2-amino-ethanesulphonic acid | |
CA2025661A1 (en) | Method of improving post-ischemic myocardial function using a thromboxane a antagonist in combination with a thrombolytic agent and combination | |
Kostka-Trabkowa et al. | Beneficial results of pentoxifylline (‘Trenta’) therapy in arteriosclerosis obliterans: possible mechanism of action | |
Saito et al. | A novel modified tissue-type plasminogen activator (t-PA), E6010, gradually increases coronary blood flow after thrombolysis compared with native t-PA, urokinase and balloon catheter occlusion-reperfusion | |
Schaub | Ciprostene, a stable prostacyclin analog, produces peripheral vasodilation, platelet inhibition and increased clot dissolution in the cat | |
EP3311812A1 (en) | COMBINATION OF TAFIa INHIBITOR WITH PLASMINOGEN ACTIVATOR | |
Li et al. | Inhibition of vasoconstrictor mechanisms by dazoxiben in the rat mesenteric vasculature | |
Ohyanagi et al. | Extended use of fluosol emulsion in acute myocardial ischemia treatment | |
GB2197195A (en) | Urokinase compositions for treating thrombosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
RH1 | Patent not in force |